NovoCure Limited (NASDAQ:NVCR) Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its holdings in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 17.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 294,639 shares of the medical equipment provider's stock after buying an additional 43,108 shares during the quarter. Quantinno Capital Management LP owned 0.27% of NovoCure worth $8,780,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. GeoWealth Management LLC purchased a new position in shares of NovoCure during the 4th quarter valued at approximately $27,000. Lindbrook Capital LLC increased its holdings in shares of NovoCure by 189.2% during the 4th quarter. Lindbrook Capital LLC now owns 1,854 shares of the medical equipment provider's stock valued at $55,000 after purchasing an additional 1,213 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of NovoCure by 70.7% during the 4th quarter. Blue Trust Inc. now owns 1,886 shares of the medical equipment provider's stock valued at $56,000 after purchasing an additional 781 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of NovoCure during the 4th quarter valued at approximately $70,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of NovoCure by 57.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,321 shares of the medical equipment provider's stock valued at $129,000 after purchasing an additional 1,575 shares in the last quarter. 84.61% of the stock is owned by hedge funds and other institutional investors.

NovoCure Price Performance

NVCR traded up $0.30 on Friday, hitting $17.89. 725,408 shares of the company's stock were exchanged, compared to its average volume of 1,155,828. NovoCure Limited has a fifty-two week low of $14.17 and a fifty-two week high of $34.13. The company has a current ratio of 1.49, a quick ratio of 1.44 and a debt-to-equity ratio of 0.27. The firm has a 50-day moving average price of $17.70 and a 200-day moving average price of $21.79. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of -12.78 and a beta of 0.73.

NovoCure (NASDAQ:NVCR - Get Free Report) last announced its earnings results on Thursday, April 24th. The medical equipment provider reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.16. NovoCure had a negative net margin of 25.93% and a negative return on equity of 41.48%. The company had revenue of $154.99 million for the quarter, compared to analysts' expectations of $147.57 million. During the same quarter in the previous year, the company posted ($0.36) EPS. The firm's quarterly revenue was up 11.9% on a year-over-year basis. As a group, equities analysts anticipate that NovoCure Limited will post -1.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on NVCR. JPMorgan Chase & Co. dropped their price target on shares of NovoCure from $29.00 to $28.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Piper Sandler dropped their price target on shares of NovoCure from $42.00 to $34.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 23rd. Wedbush dropped their price target on shares of NovoCure from $29.00 to $27.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 16th. Finally, StockNews.com cut shares of NovoCure from a "hold" rating to a "sell" rating in a research note on Friday, April 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, NovoCure has an average rating of "Hold" and a consensus price target of $32.83.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.